Expert insight and analysis providing information directly relevant to cystic fibrosis care, through topic-focused newsletters summarizing the peer-reviewed literature and accompanying podcasts to illustrate how to apply that information in the clinic. Hosted on Acast. See acast.com/privacy for more information.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CF and Diet and Nutrition: The Changing Paradigm
38:22
38:22
Play later
Play later
Lists
Like
Liked
38:22
Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That’s the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT. The first part o…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ETI (CFTR Triple Therapy): Clinical Opportunities
28:08
28:08
Play later
Play later
Lists
Like
Liked
28:08
The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest autho…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pulmonary Exacerbations and IV Antibiotics
18:44
18:44
Play later
Play later
Lists
Like
Liked
18:44
Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care? Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explai…
…
continue reading
Race and ethnicity. How do they affect a patient’s ability to receive a timely and accurate cystic fibrosis diagnosis? How do the social determinants of health limit access to appropriate CF treatment and produce poorer outcomes? That’s what we’re here to talk about today with Dr. Jennifer Taylor-Cousar from National Jewish Health and Children’s Ho…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Pancreas, Malnutrition, and CFTR Modulators
14:24
14:24
Play later
Play later
Lists
Like
Liked
14:24
Pancreatic insufficiency. In children with CF, it’s been associated with delayed development and increased odds of developing severe lung disease. How can it be more accurately diagnosed? And what does the evidence say about the effects of treatment with CFTR modulators? That’s what we explore in this case-based podcast, with Dr. Vikesh Singh, Asso…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CF and COVID-19: The Data and the Real World
34:50
34:50
Play later
Play later
Lists
Like
Liked
34:50
Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…
…
continue reading
Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…
…
continue reading
Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Maintaining CF Infection Prevention and Control
5:50
5:50
Play later
Play later
Lists
Like
Liked
5:50
Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Clinical Considerations for Women with CF
17:23
17:23
Play later
Play later
Lists
Like
Liked
17:23
Studies have shown that adolescent and young adult women with cystic fibrosis often turn to their CF care team for answers to their questions about their sexual and reproductive health. But how prepared are CF clinicians to initiate conversations? Do they have the most current data about pregnancy decisions for women taking CFTR modulators? When sh…
…
continue reading
Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Bringing Telemedicine to the CF Clinic: A Success Story
24:23
24:23
Play later
Play later
Lists
Like
Liked
24:23
No-contact telemedicine to better protect CF clinic patients and staff during this pandemic may sound like a great idea, but is it even possible to institute? In this eCysticFibrosis Review Special Edition podcast, we find out how pulmonary and critical care specialists Dr. Dana Albon and Dr. Lindsay Somerville successfully brought telemedicine to …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CFTR, Growth & Liver Disease: A Clinical Perspective
20:25
20:25
Play later
Play later
Lists
Like
Liked
20:25
Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What’s known about CFTR modulator effects on cystic fibrosis-associated liver disease? In this eCysticFibrosis Review podcast, Drs. Darla Shores and Anna Reed from the THRIVE Pediatric Intestinal Rehabilitation Center in the Divis…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In the Clinic: Triple Combination CFTR Modulation
25:17
25:17
Play later
Play later
Lists
Like
Liked
25:17
Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who’s most likely to receive them? In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s A…
…
continue reading
Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work? In this issue, Dr. Anna Georgiopoulos, Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psyc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators
21:27
21:27
Play later
Play later
Lists
Like
Liked
21:27
New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung? In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies. Take our post-test to claim CME credits. To read a companion newsletter click he…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Continuous Alternating Therapies: A Clinical Perspective
21:26
21:26
Play later
Play later
Lists
Like
Liked
21:26
Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents? Which medications are appropriate fo…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
In The Clinic: CFTR Modification & Nutritional Deficiencies
17:59
17:59
Play later
Play later
Lists
Like
Liked
17:59
The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition? In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital’s Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings ab…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
NTM Infection: Today's Treatments & New Antibiotics in Development
3:55
3:55
Play later
Play later
Lists
Like
Liked
3:55
Volume 8, Issue 7. Part 3 Hosted on Acast. See acast.com/privacy for more information.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
NTM Infection: Risk of Patient-to-Patient Transmission in CF Centers
3:11
3:11
Play later
Play later
Lists
Like
Liked
3:11
Volume 8, Issue 7. Part 2 Hosted on Acast. See acast.com/privacy for more information.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
NTM Infection: Risks of Acquisition from the Environment
4:41
4:41
Play later
Play later
Lists
Like
Liked
4:41
Volume 8, Issue 7. Part 1 Hosted on Acast. See acast.com/privacy for more information.
…
continue reading
In this issue, Dr. Gregory Sawicki — Associate Professor of Pediatrics at Harvard Medical School and Director of the Cystic Fibrosis Center at Boston Children’s Hospital — discusses how the recent findings about the real-world use of CFTR modulators can impact clinical practice. Take our post-test to claim CME credits. To read a companion newslette…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Clinical Approaches to MDR Lung Infections
22:50
22:50
Play later
Play later
Lists
Like
Liked
22:50
Multidrug resistant lung infections present an increasingly common and increasingly dangerous threat to all individuals with cystic fibrosis. Common CF pathogens — Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Stenotrophomonas maltophilia — are all showing increasing resistance to clinicians’ usual antibiotic arm…
…
continue reading
Screening to avoid the morbidity and mortality of colorectal cancer (CRC) in patients with CF, with the incidence of CRC rising, has become an increasingly important challenge, particularly among lung transplant patients. But how and when should patients be screened? With colonoscopy or non-invasive FIT? Before or after transplant? Are there patien…
…
continue reading
Volume 7, Issue 12. In this podcast Dr. John P. Clancy reviews CFTR modulators, and discusses insights presented at the 2017 NACFC. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post CFTR Modulators: Clinical Insights appeared first on DKBmed Radio. Hosted on Acast. See a…
…
continue reading
Volume 7, Issue 10. In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD, and and identifies the current recommendations for the management of CFRD. Take our post-test to claim CME cr…
…
continue reading
Volume 7, Issue 8. In this podcast Dr. George Solomon discusses new directions in CFTR modification in the context of case studies. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post New Directions in CFTR Modification appeared first on DKBmed Radio. Hosted on Acast. See …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Nutritional Management for Individuals with CF: Practical Applications
22:49
22:49
Play later
Play later
Lists
Like
Liked
22:49
Volume 7, Issue 6. Our guest author is Amanda Leonard, MPH, RD, CDE, from the Johns Hopkins Children's Hospital in Baltimore, MD. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Nutritional Management for Individuals with CF: Practical Applications appeared first on DK…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Adherence – What You Should be Telling Your Patients
35:34
35:34
Play later
Play later
Lists
Like
Liked
35:34
Volume 7, Issue 4. Our guest author is Gregory Sawicki, MD, MPH from Boston Children's Hospital, and Harvard Medical School in Boston, MA. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Adherence – What You Should be Telling Your Patients appeared first on DKBmed Radi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Weighing the Options in Managing Exacerbations
26:47
26:47
Play later
Play later
Lists
Like
Liked
26:47
Volume 7, Issue 2. Our guest authors are Mark T. Jennings, MD, MHS and Rebecca Dezube, MD from the Johns Hopkins University School of Medicine in Baltimore, MD. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Weighing the Options in Managing Exacerbations appeared firs…
…
continue reading
Volume 6, Issue 12. Claire Wainwright, FRACP, MD and Tonia Douglas, MD cover the important topic of the Future Landscape of CFTR Modulators in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Future Landscape…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pseudomonas aeruginosa Eradication and Outcomes: Key Questions
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30
Volume 6, Issue 10. Christopher Oermann, MD covers the important topic of the Pseudomonas Eradication in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Pseudomonas aeruginosa Eradication and Outcomes: Key Q…
…
continue reading
Volume 6, Issue 8. Dr. Deepak Agrawal, MD covers the important topic of Nutritional Issues in Cystic Fibrosis in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Nutritional Issues in Cystic Fibrosis appeared…
…
continue reading
Volume 6, Issue 6. Daniel Heintz, MD and Karen McCoy, MD cover the important topic of Trends in Inhaled Antibiotic Therapy in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Trends in Inhaled Antibiotic Ther…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pulmonary Exacerbations and the Microbiology of the CF Lung
22:08
22:08
Play later
Play later
Lists
Like
Liked
22:08
Volume 6, Issue 4. Our guest author is John J. LiPuma from the University of Michigan in Ann Arbor, Michigan. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Pulmonary Exacerbations and the Microbiology of the CF Lung appeared first on DKBmed Radio. Hosted on Acast. Se…
…
continue reading
Volume 6, Issue 2. In this issue we are joined by one of our Program Directors, Dr. Noah Lechtzin from the Johns Hopkins University. Dr. Lechtzin will address the current state of CFTR modification and how it can be applied in practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click…
…
continue reading
Special Edition 2015, Part 4. Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Stuart Elborn of Queen's University in Belfast, Ireland. Dr. Elborn discusses the implications of the CAT study and how it effects his practice. The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast…
…
continue reading
Special Edition 2015, Part 3. Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. JP Clancy of Cincinnati Children's Hospital. Dr. Clancy discusses the implications of the CAT study and how it effect his practice. The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast. See acast.c…
…
continue reading
Special Edition 2015, Part 2. Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Scott Bell of the QIMR Berghofer Medical Research Institute. Dr. Bell discusses the implications of the CAT study and how it will effect his practice. The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on…
…
continue reading
Special Edition 2015, Part 1. Join us as Dr. Peter Mogayzel of the Johns Hopkins University discusses the design and findings for the CAT study with Dr. Patrick Flume of the Medical University of South Carolina. Learn about the importance of the study and how it may effect your practice. The post Breaking Coverage of CAT trial appeared first on DKB…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Agents for the management of Pseudomonas aeruginosa infection
33:39
33:39
Play later
Play later
Lists
Like
Liked
33:39
Volume 5, Issue 14. In this issue we are joined by Dr. Shawn Aaron of University of Ottawa in Ontario, Canada. Dr. Aaron will discuss infection in patients with optimal therapy of chronic Pseudomonas aeruginosa cystic fibrosis, describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibr…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Benefits of CFTR Modification Beyond FEV1 Improvement
26:27
26:27
Play later
Play later
Lists
Like
Liked
26:27
Volume 5, Issue 12. In this issue of eCysticfibrosis Review Dr. Chris Goss of the University of Washington Medical Center. Dr. Goss discusses the benefits of CFTR modification beyond Fev1 improvement through the use of patient-cases. The post Benefits of CFTR Modification Beyond FEV1 Improvement appeared first on DKBmed Radio. Hosted on Acast. See …
…
continue reading
Volume 5, Issue 10. In this issue of eCystifibrosis Review we will be join by Dr. Stuart Elborn of Queens University in Belfast, Northern Ireland. Dr. Elborn discusses the effects of CFTR-Modifying Therapies. He will present three patient-case scenarios and identify appropriate treatment options. The post The Effects of CFTR-modifying Therapies app…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Optimizing Nutrition in Individuals with Cystic Fibrosis
23:53
23:53
Play later
Play later
Lists
Like
Liked
23:53
Volume 5, Issue 8. In this issue of eCysticFibrosis Review Dr. John Pohl discuses how to optimize nutrition in individuals with CF. Through patient case-scenarios he applies best practices to achieve optimal nutrition using PERT dosing. The post Optimizing Nutrition in Individuals with Cystic Fibrosis appeared first on DKBmed Radio. Hosted on Acast…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Improving digestive capabilities in nutritionally compromised patients with CF
27:35
27:35
Play later
Play later
Lists
Like
Liked
27:35
Volume 5, Issue 6. In this issue Dr. Steven Freedman, Professor of Medicine from Harvard Medical School discusses digestive capabilities in nutritionally compromised patients with CF. Listen in as Dr. Freedman explains the importance of pancreatic enzyme replacement and present patient scenarios and best practices of treatment. The post Improving d…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
P. aeruginosa eradication and reinfection
26:56
26:56
Play later
Play later
Lists
Like
Liked
26:56
Volume 5, Issue 4. In this issue of eCysticfibrosis Review Dr. Ratjen discusses the challenges of P. aeruginosa eradication. He explains the importance to treat early and available treatment options. He also addresses whether treatment should be repeated in patients who develop recurrence of infection and how to handle patients failing eradication …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pulmonary exacerbations: diagnoses, and therapeutic regimens
36:04
36:04
Play later
Play later
Lists
Like
Liked
36:04
Volume 5, Issue 2. In this podcast Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina in Charleston, discusses pulmonary exacerbation. He provides patient case scenarios to understand the importance of pulmonary exacerbation and the ability to identify when it occurs. The post Pulmonary exacerbations…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What Does CFTR Tell Us About Lung Disease?
37:42
37:42
Play later
Play later
Lists
Like
Liked
37:42
Volume 4, Issue 12. In this issue our guest author is Dr. Patrick Sosnay, Assistant Professor at the Johns Hopkins Cystic Fibrosis Center. Dr. Sosnay will illustrate how the genetics of CF can be used to make a diagnosis or identify a CF carrier, predict how individuals with a given mutation will do clinically and allow clinicians to select current…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Behavioral Treatment to Improve Dietary Adherence and Weight Gain in Children with Cystic Fibrosis
31:44
31:44
Play later
Play later
Lists
Like
Liked
31:44
Volume 4, Issue 10. In this podcast we have guest author Lori Stark, PhD, ABPP, Professor of Pediatrics at the University of Cincinnati College of Medicine. Dr. Stark, discusses how to use “shaping” to encourage a child to eat a non-preferred food, describes the role of “attention” in maintaining behaviors incompatible with eating, and discusses th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Highlights of the 27th Annual North American Cystic Fibrosis Conference
14:30
14:30
Play later
Play later
Lists
Like
Liked
14:30
Special Edition 2014 – Steven Rowe. In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses data findings from Dr. Steven Rowe results of the G551D observational study presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah. The post Highlights of the 27th Annual North American Cystic F…
…
continue reading